Pharmaceutical companies routinely cover the cost of patient copays for expensive drugs under private insurance. A federal judge could make the practice legal for millions on Medicare as well.
The makers of Aduhelm, a drug approved last month despite concerns raised by experts about its effectiveness, have launched a website and ads designed to urge people who are worried about their memory to ask doctors about testing. But some health advocates say it is misleading because some memory loss with aging is normal.
Doctors in Washington state used human body bags filled with ice and water to rapidly cool the sickest patients affected by record heat last month.
Medicare has proposed revamping its payment rules to get more people into a diabetes prevention plan that helps them eat better, exercise more and maintain a healthier lifestyle. Out of an estimated 16 million Medicare beneficiaries whose excess weight and other risk factors make them eligible, only 3,600 have participated since 2018.
Desde que se puso en marcha en 2006, el programa de desarrollo para la carrera en geriatría ha ayudado a más de 700 estudiantes de secundaria de 10 escuelas de bajos recursos, en la ciudad de Nueva York, a adquirir experiencia práctica en cuidados geriátricos.
A group of New York senior living facilities offer teens from 10 underserved schools the chance to volunteer and get free training for entry-level health jobs, career coaching and assistance on college prep.
It could take years for follow-up studies to prove Aduhelm slows the disease — or doesn’t. Meanwhile, its maker will profit.
The potential benefits of Aduhelm are small, its effectiveness is not certain, and even the FDA Thursday shifted its guidance on who should get the drug. But physicians are dealing with an onslaught of interest from patients and their families, and figuring out which patients are best positioned to be helped by the drug will be difficult.
Aduhelm, approved by the Food and Drug Administration last month despite questions about its efficacy, could be prescribed to at least 1 million patients a year, for a price tag of about $56 billion. Experts suggest there might be better ways to spend that money.
The Biden administration is moving to undo many of the changes the Trump administration made to the enrollment process for the Affordable Care Act to encourage more people to sign up for health insurance. Meanwhile, Congress is opening investigations into the controversial approval by the Food and Drug Administration of an expensive drug that might (or might not) slow the progression of Alzheimer’s disease. Joanne Kenen of Politico, Kimberly Leonard of Insider and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Marshall Allen of ProPublica about his new book, “Never Pay the First Bill: And Other Ways to Fight the Health Care System and Win.”
The covid pandemic and President Joe Biden’s agenda — a planned $400 billion infusion of support — have focused national attention on the need to expand home- and community-based long-term care services designed to keep people out of nursing homes. But the need far outpaces the staffing.
Millions of older adults want to be comfortable going online and using digital tools to enhance their lives. But many need help. A number of groups around the country offer assistance.
Despite a hearts-and-minds campaign and millions spent in incentives, managers struggle to get staffs vaccinated against covid. Some workers have threatened to quit over the pressure to get a shot, which employers can’t afford.
Federal officials say that some of the money changing hands has corrupted doctors and endangered patients.
Across the country, doctors report that those hospitalized with covid now are largely unvaccinated. New York City lags the rest of the nation in vaccinating people 65 and older, and its efforts to reach the homebound and disabled have been late in coming and disorganized.
Criminal charges filed against two officers who injured a Colorado woman with dementia don’t address the fact that police often lack the skills to effectively deal with suspects with mental disabilities.
Phone visits became an option for many Medicare and Medicaid patients during the pandemic. Now policymakers are deciding whether they’re worth the money.
The federal approval of a controversial drug to treat Alzheimer’s disease has reignited the debate over drug prices and the way the Food and Drug Administration makes decisions. Meanwhile, President Joe Biden seeks to gain goodwill overseas as he announces the U.S. will provide 500 million doses of covid vaccine to international health efforts. Sarah Karlin-Smith of the Pink Sheet, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Chiquita Brooks-LaSure, the new administrator of the Centers for Medicare & Medicaid Services. And to mark the podcast’s 200th episode, the panelists discuss what has surprised them most and least over the past four years.
Connecticut residents who learned how to communicate with family and friends through digital technology when their nursing homes closed to visitors last year used that skill to testify remotely during legislative hearings on bills affecting them.
Chiquita Brooks-LaSure, the new head of the Centers for Medicare & Medicaid Services, said the administration will focus on getting more people insured and is interested in finding a way to alleviate the gap keeping low-income families in states that haven’t expanded Medicaid from enrolling in Affordable Care Act health plans.